Cellectis (CLLS) Consolidated Net Income (2015 - 2026)
Cellectis (CLLS) posted Consolidated Net Income of -$20.7 million for Q1 2026, up 80.83% on a QoQ basis from -$108.1 million in Q4 2025, and down 426.9% year-over-year from $6.3 million in Q1 2025.
Cellectis (CLLS) has 12 years of Consolidated Net Income data on file, last reported at -$20.7 million in Q1 2026.
- In Q1 2026, Consolidated Net Income fell 426.9% year-over-year to -$20.7 million; the TTM figure through Mar 2026 stood at -$99.7 million (down 79.26% YoY), while the FY2023 annual figure was $8.4 million, up 154.69% from the prior year.
- Consolidated Net Income improved to -$20.7 million in Q1 2026, from -$108.1 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $19.0 million in Q3 2025 and bottomed at -$108.1 million in Q4 2025.
- A 5-year average of -$12.5 million and a median of -$3.9 million in 2025 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2023 — Consolidated Net Income soared 3059.95% — and 2026, when it slumped 426.9%.
- Year by year, Consolidated Net Income stood at -$2.9 million in 2022, then surged by 557.93% to $13.1 million in 2023, then plunged by 530.66% to -$56.3 million in 2024, then plunged by 91.81% to -$108.1 million in 2025, then jumped by 80.83% to -$20.7 million in 2026.
- The last three Consolidated Net Income figures came in at -$20.7 million (Q1 2026), -$108.1 million (Q4 2025), and $19.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -20.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.72 Mn |
| Dec 31, 2025 | -108.07 Mn |
| Sep 30, 2025 | 18.95 Mn |
| Jun 30, 2025 | 10.11 Mn |
| Mar 31, 2025 | -3.93 Mn |
| Dec 31, 2024 | -56.34 Mn |
| Sep 30, 2024 | 4.64 Mn |
| Jun 30, 2023 | 13.08 Mn |
| Mar 31, 2023 | -4.69 Mn |
| Dec 31, 2022 | -2.86 Mn |
| Sep 30, 2022 | -5.72 Mn |
| Jun 30, 2022 | -442,000.00 |
| Mar 31, 2022 | -6.44 Mn |
| Dec 31, 2021 | -6.65 Mn |
| Sep 30, 2021 | -42.37 Mn |
| Jun 30, 2021 | -37.48 Mn |
| Dec 31, 2020 | -39.16 Mn |
| Sep 30, 2020 | -29.35 Mn |
| Jun 30, 2020 | -33.03 Mn |
| Mar 31, 2020 | 14.41 Mn |
| Dec 31, 2019 | -38.50 Mn |
| Sep 30, 2019 | -26.65 Mn |
| Jun 30, 2019 | -35.13 Mn |
| Mar 31, 2019 | -23.12 Mn |
| Dec 31, 2018 | -29.27 Mn |
| Sep 30, 2018 | -28.90 Mn |
| Jun 30, 2018 | -21.70 Mn |
| Mar 31, 2018 | -24.90 Mn |
| Dec 31, 2017 | -27.76 Mn |
| Sep 30, 2017 | -25.70 Mn |
| Jun 30, 2017 | -19.84 Mn |
| Mar 31, 2017 | -19.76 Mn |
| Dec 31, 2016 | -20.32 Mn |
| Sep 30, 2016 | -12.90 Mn |
| Jun 30, 2016 | -11.32 Mn |
| Mar 31, 2016 | -22.51 Mn |
| Jun 30, 2015 | -13.40 Mn |
| Mar 31, 2015 | -4.02 Mn |